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Primary careWe previously demonstrated the Healthy Eating and Active Living for Diabetes (HEALD) intervention was
effective for increasing daily steps. Here, we consider the cost-effectiveness of the HEALD intervention
implemented in primary care.
HEALD was a pedometer-based program for adults with type-2 diabetes in Alberta, Canada completed between
January 2010 and September 2012. The main outcome was the change in pedometer-determined steps/day
compared to usual care. We estimated total costs per participant for HEALD, and total costs of health care
utilization through linkage with administrative health databases. An incremental cost–effectiveness ratio
(ICER) was estimated with regression models for differences in costs and effects between study groups.
The HEALD intervention cost $340 per participant over the 6-month follow-up. The difference in total costs
(intervention plus health care utilization) was $102 greater per HEALD participant compared to usual care. The
intervention group increased their physical activity by 918 steps/day [95% CI 116, 1666] compared to usual
care. The resulting ICER was $111 per 1000 steps/day, less than an estimated cost–effectiveness threshold.
Increasing daily steps through an Exercise Specialist-led group program in primary care may be a cost-effective
approach towards improving daily physical activity among adults with type-2 diabetes. Alternative delivery
strategies may be considered to improve the affordability of this model for primary care.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Improving modiﬁable risk factors for the prevention and manage-
ment of chronic diseases like type-2 diabetes (T2D) can be cost-
effective. For example, results from the Diabetes Prevention Program
suggest the incremental costs of the intensive lifestyle intervention
were largely offset by the costs incurred through medications, blood
glucose monitoring and hospitalization (inpatient and outpatient)
(DPPRG, 2012). More recently, the highly intensive Look AHEAD
lifestyle intervention found fewer hospitalizations, lower medication
use and lower overall health care costs over 10 years of follow-up
despite not achieving the trial's primary target of reduced cardiovascular
related morbidity and mortality among adults with T2D (Espeland et al.,
2014).
Indeed, the management of diabetes is complex and expensive and
is best supported through an interdisciplinary team-based approach
(Canadian Diabetes Association, 2013). Healthy eating and active living, Centre for Nursing and Health
ca, AB T9S 3A3, Canada.
).
. This is an open access article underare key strategies for diabetes self-management, requiring varying sup-
port depending on the stage (i.e.,more support at the timeof diagnosis).
Such self-management support requires substantial resource allocation,
largely delivered in primary care settings (Bodenheimer et al., 2002);
knowing this however, few primary care-based studies have examined
the economics of supporting self-management behaviors, including
active living (Matthews et al., 2014). Health care utilization and costs
appear to be higher among adults with T2D who do not achieve recom-
mended levels of physical activity (Plotnikoff et al., 2008), suggesting
that supporting the achievement of physical activity guidelines may
offer ﬁnancial beneﬁt.
Sufﬁcient evidence exists to suggest that physical activity programs
for T2D in primary care can be effective for increasing daily physical
activity (Plotnikoff et al., 2013; Vuori et al., 2013).We recently completed
the Healthy Eating and Active Living for Diabetes in Primary Care
Networks (HEALD) trial where we demonstrated that an exercise
specialist-led lifestyle program for adults with recently diagnosed T2D
in primary care, was effective for increasing daily steps compared to
usual care controls (Johnson et al., 2015), along with a comprehensive
evaluation of the intervention (Wozniak et al., 2012). Our objective
here was to consider the cost-effectiveness of the HEALD intervention
versus usual care in a primary care setting.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Setting and sample
The complete study and evaluation design have been previously
reported (Johnson et al., 2012, 2015; Wozniak et al., 2012). Patients re-
cently diagnosed with T2D were recruited from four Primary Care Net-
works (PCNs) in Alberta, Canada. All PCNs are stand-alone physician-
lead corporations established to support family physicians through al-
lied professionals, including: Chronic DiseaseManagementNurses, Reg-
istered Dieticians, Pharmacists, Health Promotion and Prevention
Coordinators and Exercise Specialists.
For recruitment, a patient registry that included information about
the patient's medical management was used to identify and recruit
study participants through each participating PCN. An endorsement
letter from each PCN was mailed to the potential participant by staff
located at each PCN (Johnson et al., 2012). Only adults (≥18 years) who
previously received basic diabetes education and were able to read, un-
derstand and converse in English were eligible. Those with signiﬁcant
self-reported cardiovascular history on pre-screening (i.e., fainting/
dizziness on physical exertion, angina pain, pacemaker, surgery) and
current depressive symptoms were also excluded.
All participants were asked to provide their personal health number
(PHN) and consent to obtain healthcare utilization data. All data provided
was de-identiﬁed. The HEALD study was approved by the Health
Research Ethics Board at the University of Alberta; ID: Pro00008427.
We enrolled 198 people (102 intervention and 96 control) between
January 2010 and September 2012, though, for this cost–effectiveness
analysis, 186 consented for linkage with health care administrative
data (94 intervention and 92 control).
Intervention and control
Eligible participants were allocated using an interrupted time series
design (Majumdar et al., 2004). The intervention group participated in a
24-week pedometer-based walking program led by a trained Exercise
Specialist at each PCN. All four Exercise Specialists responsible for
implementing HEALD had a four-year university degree in Kinesiolo-
gy/Human Kinetics/Physical Education and professionally certiﬁed by
the Canadian Society for Exercise Physiology (CESP, 2013). Two of the
four Exercise Specialists were employed by their respective PCN, one
was seconded from another provincially funded health organization
while the third was a casual PCN employee.
For the ﬁrst 12-weeks of the intervention two group sessions lasted
approximately 1 h where participants were provided a pedometer, a
logbook and a theory-based resource manual to support individualized
goal setting,monitoring, self-efﬁcacy and social support. Participants set
their own daily step goals (i.e., a prescribed daily step goal such as
10,000 steps/day was not a component of the program) (Johnson
et al., 2012).
After the ﬁrst 12 weeks, participants were encouraged towalk faster
for 30min 3 days/week for 12weeks, and tomaintain their daily volume
step goal (e.g., 7500 steps/day) from the ﬁrst phase. Two group sessions
took place, giving similar resources, but with the behavioral target for
briskwalking using a stopwatch. Participants walked on an indoorwalk-
ing track at a local recreational facility for ~30 min, supervised and
coached by the exercise specialist, to support the experiential
component during both phases.
Those allocated to theusual care control group received a pedometer
at baseline with no additional instructions around its use and received
usual care during the same 24-week study follow-up period.
Diabetes-related outcomes
Fasting capillary blood samples were collected at point-of-care to
assess hemoglobin A1c (DCA Vantage), lipid proﬁle, and glucose(Cholestech, LDX), and resting heart rate and blood pressure were also
collected (BPTru). Anthropometric measurements including weight,
height, and waist circumference were completed and body mass index
(BMI) was calculated. All measures were collected at baseline, 3 and 6
months.
Resource use and cost estimates
Intervention costs included activity time and training of the Exercise
Specialists, administrative support personnel, recreation facilities, sup-
plies, equipment, and PCN overhead. Personnel cost estimates were
based on the expected group session time, individual counseling and
training. Unit costs, including vacation/holiday pay and beneﬁts, were
obtained from collective agreements. Overhead cost was assumed 5%,
representing the marginal impact on the PCNs. Other component
estimates were based on actual costs.
For health care resource use, only direct costs of physician services,
hospital outpatient visits and hospital inpatient admissions were
included, since the analysis was conducted from a public payer perspec-
tive. Since the analytical horizon was less than one year, discounting
was not required. All costs were adjusted to 2011 Canadian prices
because participant recruitment and follow-up occurred over three
years (2009–2012).
To estimate costs we obtained participant (i.e., HEALD and usual
care) speciﬁc utilization data for physician services, hospital outpatient
clinics (including the emergency department) and hospital inpatient
services for six months prior to and six months after the completion of
the intervention. The provincial government (Alberta Health) uses a
fee-for-service system to pay for physician services, based on a standard
schedule. For all physician services included in this study, the 2011
schedule was used (AHCIP, 2010). The cost estimates of hospital
services were the product the relative cost weight of each service and
$6371, the 2011 Alberta cost per weighted case (CIHI, 2012a). The
relative cost weights were based on separate case-based grouping.
Outpatient weights were scaled so that the cost per weighted inpatient
admission could be applied to both outpatient and inpatient events
(CIHI, 2012b). The cost estimates of inpatient and outpatient services in-
clude drug costs, however, prescription medication costs purchased
from community pharmacies were excluded. The cost of operational
overhead was included in the estimates for all services.
Health outcome (effectiveness)
The primary outcome was physical activity determined by pedome-
ters; average daily steps, measured and recorded by participants over
threedays including oneweekendday (Tudor-Locke et al., 2005), and col-
lected at baseline, 3 and 6 months.
Cost effectiveness analysis (CEA)
Incremental cost is the difference in the average cost per participant
between study groups and the incremental health effect, here, the
difference in the average number of steps per participant between
study groups. We used a regression framework to adjust incremental
cost and health outcome estimates for baseline covariates. Incremental
cost was adjusted for differences in 6-month pre-enrolment health care
cost and body mass index (BMI). Incremental steps were adjusted for
differences in baseline average steps, BMI, age and sex. The incremental
cost–effectiveness ratio (ICER) was expressed in 000s of steps, thus
representing the additional cost per 1000 additional steps achieved.
In general, cost-effective interventions: cost less (the incremental
cost is negative) and are more effective (the incremental health effect
is positive), or cost more and are more effective, but society is willing
to pay for the additional cost (Drummond et al., 2005). In the latter
scenario, the ICER is less than a threshold level that reﬂects the amount
society is willing to pay for an additional unit of health outcome.
647S.T. Johnson et al. / Preventive Medicine Reports 2 (2015) 645–650Stochastic analysis of uncertainty
To account for uncertainty due to sampling variation, we used a non-
parametric bootstrapping analysis to generate a scatter plot of incremen-
tal cost and health effect on the cost–effectiveness plane (Drummond
et al., 2005). Based on that generated distribution, a cost–effectiveness
acceptability curve (CEAC) was derived, indicating the probability of the
intervention being cost-effective at various levels of society's willingness
to pay per an additional 1000 steps.
We estimated a cost–effectiveness threshold for the intervention in
order to interpret the CEAC, since we know of no established bench-
mark cost–effectiveness threshold for additional steps/day. Following
a recently published method, the threshold was estimated as the ratio
of average cost to average health effect using the sample data of the
control group (Hyewon and Levine, 2012). This threshold reﬂects the
opportunity cost, relating to the health outcome foregone, by the reallo-
cation of resources required to implement the intervention (Claxton
et al., 2013).
Statistical analyses
All statistical analyses were performed using R version 3.0.3
[R Foundation for Statistical Computing, Vienna, Austria]. For analyses
based on the original sample the Rcmdr package for R, version 2.0-4
[Fox, Bouchet-Valat; Hamilton ON, Canada] was used. Non-parametric
bootstrap analysis was conducted with the Boot package for R [Canty,
Ripley; Hamilton ON, Canada]. Filemaker Pro Advanced version
13.0 v3 [Filemaker Inc., Santa Clara, USA] was used for general data
management.
Missing data
For the 186 participants, only about 3% of the data was missing, and
related almost entirely to the primary outcome (steps). Since the
proportion of missing data was so small, the last observation carried
forward was used to impute missing observations at 6 months and
mean value substituted any baseline observations.
Results
The main results have been previously reported (Johnson et al.,
2015). Brieﬂy, at baseline the mean age was 59.5 (SD 8.3) years, A1c
6.8% (SD 1.1), 50% women, BMI 33.6 kg/m2 (SD 6.5), systolic pressure
125.6 mm Hg (SD 16.2) and the average daily steps were 5879
(SD 3130). Daily pedometer determined steps increased for the inter-
vention compared to usual care control at 3-months (1292 [SD 2698]Table 1
Resource utilization and cost by study groupab.
Pre-enrolment period
Intervention
(n = 94)
Control
(n = 92)
Difference
Resource utilization
Physician visits 8.1 (6.0) 10.4 (11.4) −2.3 (−0.
Outpatient clinic visits 2.5 (5.1) 3.1 (4.4) −0.6 (−0.
Inpatient admissions 0.02 (0.15) 0.08 (0.27) −0.06 (−0.
Costc
Intervention
Physician 586 (549) 784 (1043) −198 (−44
Outpatient 494 (910) 706 (1230) −212 (−10
Inpatient 96 (751) 401 (1605) −305 (−60
Total 1176 (1619) 1891 (3240) −715 (−31
Data were collected between January 2010 and September 2012 in Alberta, Canada.
a All values within study groups are expressed as average per participant (sd) based on the
b For differences between study groups 95% conﬁdence intervals are shown in parentheses.
c 2011 Canadian dollars.vs. 418 [SD 2458]) and 6-months (1481 [SD 2631] vs. 336 [SD 2712];
adjusted p = 0.002).
Intervention participants used fewer health resources both prior to
and after enrolment in the study, although no differenceswere statistical-
ly signiﬁcant (Table 1). HEALD cost $340 per participant, with nearly 60%
related to intervention activities and training of the exercise specialists.
With the exception of the intervention cost, intervention participants
incurred less cost in all categories (physician, out- and in-patient costs)
compared to the controls during the follow-up period. The unadjusted
mean difference in total cost (intervention plus health care utilization)
between groupswas insigniﬁcant ($4). However, excluding the interven-
tion cost, average cost per intervention participant would be $336 less
than for control patients. HEALD participants also incurred fewer costs
in the pre-enrollment period. After adjusting for pre-enrolment cost and
BMI, the adjusted incremental cost was $102 (Table 2), although not
statistically signiﬁcant. Higher levels of pre-enrolment cost and BMI
were signiﬁcantly associated with higher follow-up costs.
In terms of health outcome, intervention participants were more
active at 6 months, by an adjusted incremental rate of 919 steps,
compared with an unadjusted increment of 393 steps (Table 3). In
both the original sample and the bootstrapped analysis the incremental
health effect was statistically signiﬁcant (Tables 2 & 3).
Based on the adjusted incremental estimates, the ICER was $111 per
1000 daily steps (Table 3). The joint distribution of the incremental cost
and health effect is shown in Fig. 2, with 69% of the bootstrap replicates
located in quadrant I (greater cost, better health outcome) and 30% in
quadrant IV, consistent with dominance by the intervention (lower
cost, better health outcome). The CEAC (Fig. 1) shows that if society is
willing to pay a greater amount for additional steps, the likelihood
that the intervention is cost-effective rises steadily to about 97% when
willingness-to-pay (WTP) reaches $1000. Based on control group
results, we estimated the implied cost-effective threshold to be $176
per additional 1000 steps (point A). At that level, the probability that
intervention would be cost-effective is about 60%. The point estimate
of the ICER is $111 (point B), clearly less than the estimated threshold.
Discussion
Our analysis suggests HEALD may be a cost-effective approach to
increasing physical activity in adults with T2D. We conservatively
estimated the total intervention cost to be $340 per participant over
the 6-month follow-up period. Including intervention costs and health
care expenses, the difference in total costs between groups was $102
per participant. Intervention participants increased their physical
activity by almost 1000 steps per day, at an incremental cost of $111
compared with usual care.Follow-up period
Intervention
(n = 94)
Control
(n = 92)
Difference
36, 4.9) 7.0 (6.0) 7.8 (6.6) −0.8 (−1.0, 2.6)
8, 1.9) 1.4 (2.6) 2.3 (4.1) −0.9 (−0.1, 1.9)
01, 0.12) 0.01 (0.10) 0.02 (0.15) −0.01 (−0.03, 0.04)
340 (0) 0 (0) 340 (0)
, 440) 469 (526) 573 (613) −104 (−62, 269)
2, 525) 330 (592) 477 (761) −147 (−51, 345)
, 670) 37 (340) 122 (913) −85 (−117, 287)
, 1460) 1176 (1248) 1172 (1844) 4 (−461, 453)
original sample.
Table 2
Results for cost and health outcome regressionsa.
Independent variables Coefﬁcient estimates (t-statistics)
Average cost Average steps
Study group (1/0) 102 (0.47) 919† (2.37)
Pre-enrolment cost 0.21§ (5.06)
Body mass index (BMI) 33.7† (2.00) −76.2† (−2.51)
Baseline average steps 0.69§ (10.9)
Age −71.2‡ (−2.99)
Male (1/0) 1093‡ (2.84)
Intercept −334 (−0.59) 8605§ (4.01)
R2 adjusted 0.13 0.51
Data were collected between January 2010 and September 2012 in Alberta, Canada.
a Based on the original sample.
† p-Value b .05.
‡ p-Value b .01.
§ p-Value b .001.
* Based on 10000 replications 
Fig. 1. Bootstrap results on the cost–effectiveness plane*. *Based on 10,000 replications.
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quality adjusted life years (QALYs) (Shaw et al., 2011). To our knowl-
edge, only one study examined the cost-effectiveness of a lifestyle
program in a Canadian T2D population. Using data from the DARE trial
(Sigal et al., 2007), Coyle et al. (2012) found that the incremental cost
per QALY gained was lowest for a combined aerobic and resistance
exercise program against all comparators (i.e., no program, aerobic
only and resistance only), concluding that a combined exercise program
wasmost cost-effective for adultswith T2D. Our results did not consider
QALYs, but rather objectively assessed physical activity behavior
(pedometer determined steps), and compared the total costs of both
groups.
Given that walking and physical activity are associated with many
health beneﬁts (Vuori et al., 2013), QALYs restrict the broad assessment
of intervention impacts (Shaw et al., 2011), limiting the true value of
increasing physical activity. Neuman, Cohen and Weinstein (2014)
comment that theoretically QALYs provide an objective threshold,
however, in reality, different approaches provide different values, each
based on different assumptions, inferences and contexts. It is impossible
to ﬁnd a single threshold to truly compare interventions (Neuman et al.,
2014). In examining cost per daily steps, we provide a unique perspec-
tive that has not been previously presented in any chronic disease
population. As a novel approach, there is no accepted benchmark or
threshold, and it is therefore up to the policymaker to determine the so-
cietal value of our outcome, appropriate to the setting and population.
Physical activity interventions can be cost-effective. In their system-
atic review, Wu et al. (2011) reported comparable cost effectiveness
outcomes across a broad range of physical activity interventions by cal-
culatingMET-hour gained per day per individual reached. UnlikeQALYs,
Wu et al., state that this approach accounts for the major parameters of
physical activity, including frequency, duration and intensity. In terms
of program delivery, they reported that individualized behavior change
and social support programs, much like HEALD, were the least cost-Table 3
Cost–effectiveness analysis.
Intervention
(n = 94)
Control
(n = 92)
Difference
Cost per participanta 1176 1172 102b (−318, 464)c
Average steps per participant 7038 6645 919d (116, 1666)c
ICERe 111
Data were collected between January 2010 and September 2012 in Alberta, Canada.
a 2011 Canadian dollars.
b Adjusted for pre-enrolment cost and body mass index (BMI), see Table 2.
c Non-parametric bootstrap 95% conﬁdence interval based on 10,000 replications.
d Adjusted for baseline average steps, body mass index (BMI), age and sex, see Table 2.
e ICER = incremental cost–effectiveness ratio = additional cost per 1000 steps =
incremental cost (102) ∕ incremental outcome (919/1000).effective interventions for increasing daily physical activity. However,
they reported that these programs demonstrated greater effect sizes,
adding 35%–43% of the guideline-recommended physical activity for
adults (Wu et al., 2011). Because they are not only effective, but also
costly, these types of programsmight be best suited for targeted groups
requiring additional support in self-management, like people with T2D.
A recentmeta-analysis of randomized controlled trials usingpedom-
eters in people with T2D found an increase in daily steps of 1822 across
7 studies (861 participants; 95% conﬁdence interval (CI): 751 to 2894
steps/day) but no improvements in glycemic control (Qiu et al., 2014).
Some have suggested that an increase in steps/day of 4000 baseline
may be a clinically relevant threshold for improving glycemic control
in T2D (Van Dyck et al., 2013). Observational data from theA  = estimated cost-effectiveness threshold ($176 per 1000 steps).
B  = ICER point estimate ($111 per 1000 steps) from original sample.
Fig. 2. Cost–effectiveness acceptability curve.
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day above baseline between 1000–2500 reduce the risk of dysglycemia
and other cardiovascular related events over 5 years of follow-up
among those with a higher cardiometabolic risk proﬁle (Dwyer et al.,
2011; Yates et al., 2014). Hence, we argue that although a 1000 steps/
day increase might seem low, the increase in daily steps reported here
may have behavioral, clinical, and economic relevance.
Our results are important for questions around program implemen-
tation and sustainability. It is true that ‘pedometers cost buttons’ (Shaw
et al., 2011), but good quality pedometers alone are insufﬁcient to
support increases in daily ambulatory activity over the longer term.
Pedometers have been likened to a computer without an operating
system; that is, providing a pedometer without structured support
that incorporates behavioral theory (i.e., goal setting and tracking with
a degree of social support) renders the device insufﬁcient for behavior
change (Tudor-Locke et al., 2005). HEALD was designed to include be-
havioral theory and experiential learning in a hospitable environment
(a recreational facility with a walking track) and the control group re-
ceived a pedometer without instruction or support. Hence, the costs be-
yond simply providing patientswith pedometersmust be considered by
primary care providers to successfully implement a program to increase
daily physical activity.
Moreover, HEALD was designed using group sessions, helping to
reduce the costs per patient that incur with face-to-face counseling
(Vuori et al., 2013). Once well established, more people per session
could register, therefore reducing per participant costs. More research
is needed to determine the optimal class size for effective and efﬁcient
delivery. As well, training can be considered an initial start-up cost,
reducing overall cost over time. Regarding program sustainability, by
choosing an everyday outcome measure (i.e. steps), continuous pro-
gram and individual evaluation is possible with minimal resources,
extra training and other costs and thus potentially contributing towards
long-term program adoption (Matthews et al., 2014).
This analysis has various strengths. The lack of current literature
regarding economic evaluation of physical activity interventions and
especially controlled trials, attests to the need of this type of analysis.
We were able to capture the health care costs of both groups. As well,
over 93% of the original participants consented for administrative data
linking, maintaining our intended sample size and controlling any
differences between the groups of consenting participants. Despite the
strengths we have outlined we acknowledge that this study has some
weaknesses. Firstly, we used steps/day as our effectiveness measure
and because steps are only one component of total daily physical
activity the use of an accelerometermay have provided a better objective
estimate of daily physical activity across both groups. Nevertheless, steps
were the intended target of the intervention. Secondly, we limited our
follow-up to a one-year time horizon and hence we have constrained
the potential to estimate the long-term impact of the HEALD interven-
tion. Lastly, economic analyses drawn from a healthcare setting where
all patients have universal healthcare coverage may limit the generaliz-
ability of our ﬁndings. For example, one exercise specialist to manage
hundreds if not thousands of diabetes patients in this type of setting
requires consideration given that they may have other responsibilities
(e.g., other patient populations).
In a time of priority shifting and results-based budgeting, without
using QALYS, it is difﬁcult to compare the cost-effectiveness of HEALD
to other health interventions. Though our analysis is unique, it will
take extra effort to present ﬁndings to policymakers and reinforce the
longer-term impacts and overall health beneﬁts of this walking
program. This approach also considers the limitation of the short-term
nature of our study.Whilewe considered the cost of hospital, outpatient
and physician services, we were unable to estimate differences in
costs of lab tests or medications between groups, although given the
short-term follow-up, and lack of change in clinical parameters
(Johnson et al., 2015), it is unlikely that these differed between study
groups.Conclusion
Health Eating andActive Living forDiabetes (HEALD)was an effective
program in increasing daily steps among people with type-2 diabetes
in primary care, which over a lifetime, may have worthwhile health
beneﬁts. Our economic analysis suggests that the intervention may be
cost-effective.
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